DOS 2018

232 · DOS Abstracts The long-term effect of high volume image-guided injection in the chronic Patella Tendinopathy: a prospective case series Lene Lindberg Miller, Torsten Grønbech Nielsen, Bjarne Mygind-Klavsen, Martin Lind Div. of Sports Trauma, Orthopedic Dept. , Aarhus University Hospital, Denmark Background: This present study evaluated the long-term effect of high volume image-guided injection (HVIGI) for chronic Patella Tendinopathy (PT). Purpose / Aim of Study: Does HVIGI-treatment for chronic non-insertional PT improve function and reduce pain at a long-term follow-up? Materials and Methods: Patients with resistant PT who failed to improve with a 3-month heavy slow resistance program were included in the study. Maximal tendon thickness and neovascularisation was assessed with ultrasound and power Doppler. All the tendinopathic patella tendons were injected, ultrasound guided, with 10 mL of 0.5%Marcaine, 0.5 mL Triamcinolonacetonid (40mg/mL) and 40 mL of 0.9% NaCl saline solution under real time ultrasound guidance. All outcome measures were recorded at baseline and after one year. A standardized heavy slow resistance protocol was prescribed after HVIGI-treatment. Clinical outcome was assessed with the Victorian Institute of Sports Assessment- Patella tendon (VISA-P) questionnaire. Findings / Results: Thirty-six HVIGI procedures were performed in the period 2013-2016. The study included a series of 24 procedures in 22 patients (20 men, 2 women). Mean age 31,9 (range 18-52). Mean duration of symptoms before HVIGI was 44 months. The baseline VISA-P score of 39±16 (range 15- 67) improved to 65±22 (range 20-94) by 1 year (p=0,001). 73% of the pa- tients had more than a 10 point improvement at the VISA-P score after one year. Elleven patients (31%) did not respond to treatment with continued pain and referred to surgery (5 patients) or additional HVIGI treatment (6 patients/7 procedures) before 1- year follow-up. Conclusions: HVIGI-treatment for chronic PT significantly improved function and reduced pain (VISA-P) at long-term follow-up. 31% of the patients did not respond to a single HVIGI treatment. 173.